This pilot phase I trial investigates the safety of atezolizumab (MPDL3280A) in patients with cancer undergoing adoptive cell transfer (ACT). The study enrolls 40 participants with Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, or Unresectable Malignant Solid Neoplasm.
Study Procedures and Assessments
Participants receive atezolizumab intravenously (IV) over 30-60 minutes, repeated every 21 days for a total of 17 doses up to 12 months, contingent on the absence of disease progression or unacceptable toxicity. During the study, patients undergo computed tomography (CT) and magnetic resonance imaging (MRI) scans. They also undergo tissue biopsies and blood specimen collection for laboratory biomarker analysis and correlative studies.
Efficacy and Follow-up
The study aims to evaluate the safety of atezolizumab administration following ACT. Secondary objectives include assessing the expansion of engrafted T cells in the peripheral blood and tumor microenvironment, evaluating the phenotype and function of these T cells, observing anti-tumor activity, and evaluating response rates using immune-related Response Criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, or other tumor-specific criteria. Furthermore, the study will evaluate survival outcomes and progression-free survival using irRC and RECIST v1.1, or other tumor-specific criteria. Following treatment completion, patients are followed up at 4 weeks, 8 weeks, and then every 3 months thereafter.